JP2024512633A5 - - Google Patents

Info

Publication number
JP2024512633A5
JP2024512633A5 JP2023560024A JP2023560024A JP2024512633A5 JP 2024512633 A5 JP2024512633 A5 JP 2024512633A5 JP 2023560024 A JP2023560024 A JP 2023560024A JP 2023560024 A JP2023560024 A JP 2023560024A JP 2024512633 A5 JP2024512633 A5 JP 2024512633A5
Authority
JP
Japan
Prior art keywords
containing seq
antigen
seq
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023560024A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024512633A (ja
JP7659654B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/058123 external-priority patent/WO2022207554A1/en
Publication of JP2024512633A publication Critical patent/JP2024512633A/ja
Publication of JP2024512633A5 publication Critical patent/JP2024512633A5/ja
Application granted granted Critical
Publication of JP7659654B2 publication Critical patent/JP7659654B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023560024A 2021-03-30 2022-03-28 抗sema3a抗体およびその用途 Active JP7659654B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21165960 2021-03-30
EP21165960.2 2021-03-30
PCT/EP2022/058123 WO2022207554A1 (en) 2021-03-30 2022-03-28 Anti-sema3a antibodies and uses thereof

Publications (3)

Publication Number Publication Date
JP2024512633A JP2024512633A (ja) 2024-03-19
JP2024512633A5 true JP2024512633A5 (https=) 2025-02-21
JP7659654B2 JP7659654B2 (ja) 2025-04-09

Family

ID=75302351

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023560024A Active JP7659654B2 (ja) 2021-03-30 2022-03-28 抗sema3a抗体およびその用途

Country Status (14)

Country Link
US (2) US12384843B2 (https=)
EP (1) EP4314047A1 (https=)
JP (1) JP7659654B2 (https=)
KR (1) KR20230162800A (https=)
CN (1) CN117396504A (https=)
AR (1) AR125240A1 (https=)
AU (1) AU2022251786A1 (https=)
BR (1) BR112023018061A2 (https=)
CA (1) CA3215274A1 (https=)
IL (1) IL307233A (https=)
MX (1) MX2023011619A (https=)
PE (1) PE20240357A1 (https=)
TW (1) TWI898130B (https=)
WO (1) WO2022207554A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250002588A1 (en) 2023-04-07 2025-01-02 Diagonal Therapeutics Inc. Bispecific agonistic antibodies to activin a receptor like type 1 (alk1)
CN118598995B (zh) * 2024-06-24 2025-12-12 苏州大学 一株抗sema7A功能性单抗10A6的制备及其在SLE中的抗炎作用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
US9296820B2 (en) 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
EP1740615B1 (en) 2004-03-31 2014-11-05 Genentech, Inc. Humanized anti-tgf-beta antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN101720368A (zh) 2007-03-09 2010-06-02 中国抗体制药有限公司 储备多样性最大化的功能性人化抗体文库之构建及应用
JP6372040B2 (ja) * 2013-02-06 2018-08-15 公立大学法人横浜市立大学 抗セマフォリン3a抗体、並びにこれを用いたアルツハイマー病及び免疫・炎症性疾患の治療
AU2016346595B2 (en) * 2015-10-27 2019-11-14 Pangen Biotech Inc. Antibody to be cross-linked to human and mouse Sema3A, and use thereof
KR101854529B1 (ko) 2015-10-27 2018-05-04 (주) 팬젠 인간 및 마우스 Sema3A에 교차결합하는 항체 및 그의 용도
WO2020225400A1 (en) * 2019-05-09 2020-11-12 Boehringer Ingelheim International Gmbh Anti-sema3a antibodies and their uses for treating eye or ocular diseases
US12509512B2 (en) * 2019-06-27 2025-12-30 Ramot At Tel-Aviv University Ltd. Semaphorin 3A antibodies and uses thereof

Similar Documents

Publication Publication Date Title
TWI673287B (zh) 抗b7-h3抗體、其抗原結合片段及其醫藥用途
AU2009245354C1 (en) Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof
CN110881274B (zh) 识别tau的抗体
JP7623699B2 (ja) タウ認識抗体
JP2020517249A5 (https=)
JP2019525724A (ja) タウ認識抗体
JP2010502183A5 (https=)
RS57026B1 (sr) Anti-n3pgiu amiloid beta peptid antitela i njihova upotreba
CN114667296B (zh) 一种双特异性抗体及其用途
JP7554351B2 (ja) ヒトil-33に結合する抗体、その調製方法および用途
JP2024512633A5 (https=)
AU2016319433A1 (en) Anti-EphA4 antibody
RU2007118670A (ru) Ангиопоэтин-2-специфические связывающие агенты
CN114573702A (zh) 一种新型肿瘤衔接器治疗药物的开发和应用
JP2026016483A (ja) 抗ヒトtlr7抗体
JP2023522212A5 (https=)
JP2025529812A (ja) 甲状腺刺激ホルモン受容体に結合する抗体及びその使用
JP2023547662A5 (https=)
CN112243443A (zh) 抗trop-2抗体、其抗原结合片段及其医药用途
JP2024543822A5 (https=)
RU2023127516A (ru) Антитела к sema3a и их применение
US20190225680A1 (en) Tenascin Epitope and Antibodies Thereto
JP2023541179A5 (https=)
JP2023512320A5 (https=)
WO2025228315A1 (en) Anti-n3pglu amyloid beta antibodies and uses thereof